(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 10.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Apellis Pharmaceuticals's revenue in 2025 is $754,649,000.On average, 10 Wall Street analysts forecast APLS's revenue for 2025 to be $114,082,727,299, with the lowest APLS revenue forecast at $89,084,902,514, and the highest APLS revenue forecast at $130,962,636,670. On average, 10 Wall Street analysts forecast APLS's revenue for 2026 to be $110,895,801,421, with the lowest APLS revenue forecast at $95,702,493,798, and the highest APLS revenue forecast at $121,743,473,240.
In 2027, APLS is forecast to generate $135,313,450,359 in revenue, with the lowest revenue forecast at $116,679,247,849 and the highest revenue forecast at $158,367,547,140.